www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

   

Merck's experimental AIDS vaccine fails

(AP)
Updated: 2007-09-23 19:09

TRENTON, N.J. - In a disappointing setback, a promising experimental AIDS vaccine failed to work in a large international test, leading the developer to halt the study. Merck & Co. said Friday that it is ending enrollment and vaccination of volunteers in the study, which was partly funded by the US National Institutes of Health.

It was a high-profile failure in the daunting quest to develop a vaccine to prevent AIDS. Merck's vaccine was the farthest along and was closely watched by experts in the field.

Officials at the company, based in Whitehouse Station, N.J., said 24 of 741 volunteers who got the vaccine in one segment of the experiment later became infected with HIV, the virus that causes AIDS. In a comparison group of volunteers who got dummy shots, 21 of 762 participants also became infected.

"It's very disappointing news," said Keith Gottesdiener, head of Merck's clinical infectious disease and vaccine research group. "A major effort to develop a vaccine for HIV really did not deliver on the promise."

Michael Zwick, an HIV researcher at Scripps Research Institute, said the vaccine's failure is unfortunate. But he said it's too soon to know if other vaccines using the same strategy would also fail.

"It's par for the course in the HIV field," he said of the Merck result.

The volunteers in the experiment were all free of HIV at the start. But they were at high risk for getting the virus: Most were homosexual men or female sex workers. They were all repeatedly counseled about how to reduce their risk of HIV infections, including use of condoms, according to Merck.

In a statement, the NIH said a data safety monitoring board, reviewing interim results, found the vaccine did not prevent HIV infection. Nor did it limit severity of the disease "in those who become infected with HIV as a result of their own behaviors that exposed them to the virus" - another goal of the study.

Merck's was the first major test of a new strategy to prevent HIV infection. The first wave of attempts to develop a vaccine tried to stimulate antibodies against the virus, but that hasn't worked so far.

The new effort - an approach that Gottesdiener said is being tried in most other current research - is aimed at making the body produce more of a crucial immune cell called killer T cells. The goal is to simultaneously "train" those cells, like an army, to quickly recognize and destroy the AIDS virus when it enters cells in the bloodstream.

Zwick said some researchers still are working on vaccines to neutralize the AIDS virus. He thinks ultimately what's needed is one that combines that approach with a way to stimulate and train killer T cells.

Merck and the HIV Vaccine Trials Network, an international collaboration of researchers and institutions funded by the NIH, co-sponsored the study. The experiment, called STEP, began in December 2004 and had enrolled 3,000 volunteers in Australia, Brazil, Canada, the Dominican Republic, Haiti, Jamaica, Peru, Puerto Rico and the United States.

The results announced Friday involved volunteers who researchers thought would benefit most because they had never been exposed to the particular cold virus used in the vaccine.

Wall Street, on a generally upbeat day, showed little reaction to the news, with Merck shares rising 44 cents to $51.82.

Analyst Steve Brozak of WBB Securities said the vaccine was considered the most promising candidate both by Wall Street and the science community. He said a vaccine is the only financially feasible way to fight the AIDS epidemic in poor countries and that the company that comes up with the first successful shot would have "a license to print money."

"You're talking about a Carl Sagan kind of number - billions and billions" of dollars, he said.

The Merck vaccine, known only as V520, also was being tested in a similar study in South Africa and in two smaller studies, which also were halted.

The Merck vaccine failure is a "deep disappointment and a scientific setback for the AIDS vaccine field," the AIDS Vaccine Advocacy Coalition said in a statement. However, the nonprofit group added that "while this is a disappointment, it is in no way the end of the search for an AIDS vaccine."



Related Stories  
Top World News  
Today's Top News  
Most Commented/Read Stories in 48 Hours
主站蜘蛛池模板: 免费高清欧美一区二区视频 | 亚洲一级大片 | 日韩视频网 | 草草影院www色极品欧美 | 国产成人高清 | 国产成人精品久久 | 成人免费观看高清在线毛片 | 久久国产情侣 | 亚洲在线视频网站 | 国产一级一级毛片 | 国产精品视频第一区二区三区 | 久久国产精品99久久小说 | 日韩欧美一区二区精品久久 | 老司机午夜在线视频免费观 | 国产在线欧美日韩精品一区二区 | 久久人 | 另类专区另类专区亚洲 | 国产精品久久久久一区二区 | 国产一区影视 | 一区二区三区四区视频在线 | 欧美人成在线 | 日产毛片 | 国产在线日韩 | 亚洲资源在线 | 日韩在线视频免费 | 91免费看视频 | 日本草草视频在线观看 | 成人a免费视频播放 | 在线亚洲精品国产波多野结衣 | 亚洲不卡视频在线观看 | 91国内精品久久久久影院优播 | 成人免费观看www在线 | 在线观看免费精品国产 | 欧美在线小视频 | 99免费在线观看 | 亚洲精品久久久久影院 | 在线播放免费一级毛片欧美 | 很黄很色的免费视频 | 国产精品三级国语在线看 | 国产欧美成人一区二区三区 | theav视频在线观看 |